Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (NASDAQ: PAVM) generates news across medical devices, diagnostics, and digital health, reflecting its role as a diversified, commercial-stage medical technology company. Its news flow often covers developments at the parent company level as well as at its subsidiaries, Lucid Diagnostics Inc. and Veris Health Inc., which focus on cancer prevention diagnostics and digital cancer care.
Investors following PAVM news can expect updates on corporate actions, such as the announced 1-for-30 reverse stock split intended to help the company meet Nasdaq’s minimum bid price requirement and maintain its listing on the Nasdaq Capital Market. Company communications also highlight business updates, quarterly financial results, and information on balance sheet and capital structure decisions, often furnished through press releases and Form 8-K filings.
News related to Lucid Diagnostics, a subsidiary of PAVmed, frequently focuses on the commercialization and clinical performance of the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Recent announcements have described large real-world datasets on non-endoscopic esophageal precancer detection, Medicare coverage processes, and participation in medical and investor conferences.
Updates involving Veris Health typically center on the Veris Cancer Care Platform and its deployment in clinical settings. For example, PAVmed and Veris have reported the launch of the commercial phase of a long-term strategic partnership with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, focused on enhancing personalized cancer care for patients undergoing systemic cancer therapy.
This PAVM news page brings together these types of announcements, allowing readers to track financial disclosures, technology and platform milestones, regulatory and reimbursement developments, strategic partnerships, and corporate governance actions over time.
PAVmed Inc. announced that a wholly owned subsidiary has signed a purchase agreement for CapNostics, LLC, maker of the EsophaCap® device, which is FDA-cleared and CE Mark certified for non-endoscopic esophageal cell collection. This acquisition aims to enhance PAVmed's portfolio in early detection and monitoring of esophageal diseases, particularly esophageal precancer. The deal includes a long-term consulting agreement with Martin Von Dyck, the owner of CapNostics, and a manufacturing agreement with its contract manufacturer. This strategic move is expected to drive shareholder value.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a virtual investor event on October 26, 2021, from 1 to 3 PM EDT, focused on its digital health subsidiary, Veris Health. The event will showcase Veris’ innovative technology aimed at enhancing cancer care through remote monitoring and data analytics. Panelists include executives from PAVmed and the Stanford Cancer Institute. Veris seeks FDA clearance for its intelligent implantable vascular access port, targeting a launch for H2 2022. The event includes a Q&A session for participant engagement.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) recently announced that its subsidiary, Lucid Diagnostics Inc., has filed a Form S-1 registration with the SEC for a proposed initial public offering of its common stock. The offering details, including the number of shares and price range, are yet to be determined. Lucid intends to list on Nasdaq under the ticker 'LUCD.' Cantor Fitzgerald & Co. and Canaccord Genuity LLC will manage the offering, with BTIG, LLC and Needham & Co., LLC as co-managers. This offering aims to bolster Lucid’s market presence and product development.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced that its subsidiary Veris Health Inc. has joined Microsoft for Startups, gaining access to advanced technology and support to expedite its remote digital healthcare platform focused on cancer care. Veris is collaborating with Loka Inc. for platform development on Microsoft Azure, integrating AI and IoT for better patient monitoring. Veris aims for FDA clearance of its intelligent implantable vascular access port by H2-2022, enhancing data-driven patient care and optimizing treatment outcomes.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has announced its participation in three prominent conferences: the Lake Street Capital Market's Best Ideas Growth Conference on September 14, 2021, the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021, and The MedTech Conference on September 30, 2021. The presentations will highlight PAVmed's diversified medical technology pipeline, which aims to address unmet clinical needs. For detailed information, visit the company's website.
PAVmed reported a business update highlighting progress in its subsidiary, Lucid Diagnostics, for Q2 2021. Lucid conducted 202 EsoGuard tests, a 110% increase sequentially, and partnered with UpScriptHealth for telemedicine support. Lucid also received CE Mark certification for its EsoCheck and EsoGuard devices, enhancing marketability in Europe. Financially, PAVmed incurred a GAAP net loss of approximately $11.5 million, or $(0.14) per share, while cash reserves increased to $43.2 million. The company's strategic initiatives aim for long-term growth and shareholder value enhancement.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced the launch of three Lucid Test Centers in Phoenix for testing patients with gastroesophageal reflux disease (GERD). This initiative aims to enhance EsoGuard commercialization and target primary care physicians (PCPs) for early detection of esophageal precancer. The centers utilize the EsoCheck device for a rapid, non-invasive procedure. A single nurse practitioner can conduct up to twenty tests daily. Lucid plans to expand the program across Western U.S. states, operating modestly with fixed costs and margins.
PAVmed (Nasdaq: PAVM, PAVMZ) announced that Dr. Lishan Aklog, Chairman and CEO, will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT. Investors can access the live webcast here. A replay will be available on the PAVmed website.
PAVmed focuses on innovative medical technologies, with products for early detection of esophageal cancer and minimally invasive interventions.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced that Aster Angagaw has joined the Board of Directors of its subsidiary, Lucid Diagnostics. Angagaw brings extensive experience in healthcare and business transformation, previously serving prominent roles at Owens & Minor and ServiceMaster Brands. PAVmed's chairman, Lishan Aklog, emphasized her expertise will enhance Lucid's growth strategy in precancer screening technologies. This appointment is expected to strengthen Lucid's leadership as it aims for long-term expansion.
Summary not available.